India Defends IP Framework Amid Global Pressure on Generic Medicines

India continues to play a central role in the global pharmaceutical landscape as a leading supplier of affordable generic medicines. The country provides nearly 20% of the world’s generics, supporting access to essential healthcare across both developing and developed markets.

At the same time, India faces ongoing pressure—particularly from the United States—regarding its intellectual property (IP) framework for pharmaceuticals. Critics argue for stronger protection, while India maintains that its system is fully compliant with international trade rules, including WTO obligations.

According to policy experts, India’s approach reflects a deliberate balance between protecting innovation and ensuring access to affordable medicines. The issue highlights long-standing differences between the two countries on how IP should be applied in the healthcare sector.

As global demand for accessible treatments grows, India’s position remains a key factor in shaping discussions on IP, innovation, and public health worldwide.